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Abstract
HLA-G is a non-classical HLA class-Ib molecule expressed mainly by the extravillous cytotrophoblasts (EVT) of the placenta.
The expression of HLA-G on these fetal cells protects the EVT cells from immune rejection and is therefore important for a
healthy pregnancy. The mechanisms controlling HLA-G expression are largely unknown. Here we demonstrate that miR-
148a and miR-152 down-regulate HLA-G expression by binding its 39UTR and that this down-regulation of HLA-G affects
LILRB1 recognition and consequently, abolishes the LILRB1-mediated inhibition of NK cell killing. We further demonstrate
that the C/G polymorphism at position +3142 of HLA-G 39UTR has no effect on the miRNA targeting of HLA-G. We show that
in the placenta both miR-148a and miR-152 miRNAs are expressed at relatively low levels, compared to other healthy
tissues, and that the mRNA levels of HLA-G are particularly high and we therefore suggest that this might enable the tissue
specific expression of HLA-G.
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Introduction
HLA-G is a nonclassical HLA class Ib molecule that possesses
unique features, such as low polymorphism, restricted expression
and seven spliced isoforms [1,2,3]. HLA-G expression is restricted
mainly to the EVT cells of the placenta, which is of fetal origin.
The EVT cells invade the uterine mucosa (the decidua) and the
spiral arteries [4,5]. The restricted expression of HLA-G is thought
to provide immunoprotection to the semiallogenic embryo,
especially from the decidual NK cells, which are the major
lymphocyte population at the fetal-maternal interface, early during
pregnancy [4].
NK cell activity is balanced by signals from activating and
inhibitory receptors and in that regard, HLA-G inhibits NK
activity mainly via the interaction with the inhibitory receptor
LILRB1 [6,7]. LILRB1 has a higher affinity to HLA-G than other
HLA class-I molecules due to increased avidity formed as a result
of HLA-G disulfide-dimers and trimers [6,7]. HLA-G also binds
the inhibitory receptor KIR2DL4 with very low affinity, however,
the necessity of KIR2DL4 for reproductive success has been
questioned [8,9,10]. HLA-G is important for a successful
pregnancy and low expression levels of HLA-G at the fetal-
maternal interface are associated with pregnancy complications,
such as preeclampsia [11]. It is also expressed by tumors, virus-
infected cells and by transplanted organs [12]. The restricted
expression of HLA-G and the fact that HLA-G on the one hand is
important for successful embryo implantation and fetal survival
but, on the other hand, being potentially detrimental in tumors
and viral infections suggest that the expression of HLA-G is tightly
regulated [13]. However the mechanisms controlling HLA-G
expression are currently largely unknown.
Although the HLA-G protein shows low polymorphism in the
human population, especially when compared with other HLA
class-I molecules, it possesses high polymorphism in its promoter
region and in its 39untranslated region (UTR). A 14 bp insertion/
deletion polymorphism in the 39UTR of HLA-G has been
associated with RNA stability, however it is not clear whether or
not this polymorphism can indeed affect HLA-G expression [13].
It has been suggested that the expression of HLA-G is influenced
by a C/G polymorphism at position +3142 of the gene, which
resides in the 39UTR of HLA-G [14]. This site was also suggested
to be a site targeted by some miRNAs [15] and the presence of
guanine instead of cytosine at this position was claimed to favor
HLA-G 39UTR targeting by miRNAs.
MiRNAs are ,22 nt long non-coding RNA molecules that
usually negatively regulate gene expression post-transcriptionally,
mainly by binding to the 39UTR of mRNAs [16,17]. Such binding
results in either translational inhibition or in mRNA degradation
[16,17]. It is now known that miRNAs play a pivotal role in many
biological and pathological processes [18]. Three miRNAs were
suggested to target the 39UTR of HLA-G: miR-148a, miR-148b
(that share an identical seed) and miR-152 [15]. A recent study by
Zhu and colleagues showed that miR-152 down-regulates HLA-G
expression by targeting its 39UTR [19]. However, it is still
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the gene can indeed affect HLA-G expression, whether the
miRNA-mediated down-regulation of HLA-G has functional
consequences (for example, effect on inhibitory receptor binding
to HLA-G), whether miR-148 could also target HLA-G and what
is the expression pattern of these miRNAs in the relevant tissue,
the placenta.
Here we demonstrate that both miR-148a and miR-152 down-
regulate HLA-G expression and that this down-regulation has
functional consequences, as it prevents HLA-G-mediated inhibi-
tion of NK cell killing, through the LILRB1 inhibitory receptor.
We further show that, contrary to what has been suggested, the C/
G polymorphism has no influence on HLA-G regulation by these
miRNAs. Finally, we show that the expression levels of the HLA-
G-targeting miRNAs in the placenta are low as compared to other
tissues and that the mRNA levels of HLA-G in the placenta are
high. Therefore, we suggest that this might allow the expression of
HLA-G in the placenta and not in other healthy tissues.
Materials and Methods
Cells
We used the RKO cell line (obtained from ATCC) and the
MHC class I-negative human B lymphoblastoid cell line 721.221
[20]. Two transfectants were generated: 721.221 cells expressing
HLA-G with a guanine nucleotide at position +3142 (with or
without its 39UTR). In addition, an additional transfectant was
generated, expressing HLA-G with its 39UTR with a cytosine
nucleotide at position +3142 of the gene. To generate the
721.221/HLA-G transfectants, the HLA-G protein with its
39UTR was amplified from JEG-3 cells (expressing guanine at
position +3142, verified by sequencing compared to the published
sequence, accession number NM_002127) using the following
primers: Fw HLA-G primer: 59 CGGGATCCGCCGCCAC-
CATGGTGGTCATGGCGCCC 39. Rv HLA-G +39UTR prim-
er: 59GGCATTCAAAGTTCTCATGTCTTCCATTTA 39.
The plasmid expressing HLA-G with a cytosine base in position
+3142 in the 39UTR was generated by PCR. First, the upstream
fragment was amplified using the 59 HLA-G edge primer,
described above and an internal 39 primer bearing the mutation
(59 tagctcagtggaccacaaatt 39). The downstream fragment was
amplified using an internal 59 primer bearing the mutation
(59aatttgtggtccactgagcta 39) and the 39 HLA-G+39UTR edge
primer, described above. Next, both purified fragments were
mixed together with the 59 edge primer and the 39 edge primer to
generate the mutated full-length cDNA.
To generate a plasmid expressing HLA-G without its 39UTR,
the same Fw primer was used and the following Rv primer was
used: 59HLA-G GGAATTCTCAATCTGAGCTCTTCTTTCT
39. The various fragments were then cloned into the pcDNA3
mammalian expression vector and stably transfected into the
721.221 cell line.
Peripheral blood lymphocytes were isolated from healthy female
donors using Ficoll gradient. NK cells were further purified by
using the human NK cell isolation kit and the autoMACS
instrument (Miltenyi Biotec), according to the manufacturer’s
instructions. The identity of NK cells was confirmed by FACS.
Purity was .98%. LILRB1-positive NK clones were grown in
culture in the presence of 10 ng/ml IL-15 (PeproTech) and then
used for NK cytotoxicity assays.
Lentiviral constructs and transduction
The following oligonucleotides were used to generate artificial
short hairpin RNAs that function as orthologs of pre-miRNA
hairpins (the sequences of the mature miRNAs are in capital
letters):
Fw miR148a: 59gatccccTCAGTGCACTACAGAACTTTGT-
ttcaagagaACAAAGTTCTGTAGTGCACTGAtttttggaaa 39
Rv miR-148a: 59agcttttccaaaaTCAGTGCACTACAGAACT-
TTGTtctcttgaaACAAAGTTCTGTAGTGCACTGA ggg 39.
Fw miR-152:
59gatccccTCAGTGCATGACAGAACTTGGttcaagagaC-
CAAGTTCTGTCATGCACTGAtttttggaaa 39.
Rv miR-152: 59agcttttccaaaaaTCAGTGCATGACAGAACT-
TGGtctcttgaaCCAAGTTCTGTCATGCACTGAggg 39.
Fw miR-BART12: 59 gatcccc TCCTGTGGTGTTTGGTGT-
GGTTttcaagaga AACCACACCAAACACCACAGGAtttttggaaa
39
Rev miR-BART12: 59 agcttttccaaaaa TCCTGTGGTGTTT-
GGTGTGGTT tctcttgaa AACCACACCAAACACCACAGGA
ggg 39
The specific oligonucleotides of the different miRNAs were
annealed and inserted into the pTendoplasmic reticulum vector
and then were excised from the vector together with the H1 RNA
polymerase III promoter into the lentiviral vector SIN18-pRLL-
hEFIp-EGFP-WRPE, as described [21]. In all experiments, miR-
BART12 miRNA of EBV was used as the control microRNA.
Lentiviruses were produced by transient three-plasmid transfec-
tion, as described [21]. These viruses were used to transduce the
cell lines used, in the presence of polybrene (5 g/ml).
Immunohistochemistry
The institutional review board of Hadassah–Hebrew University
Medical Centers approved the use of decidual and placental waste
material from healthy elective first-trimester pregnancy termina-
tions, according to the principles of the Helsinki convention.
Immunohistochemistry for HLA-G was performed on first
trimester human placental formalin fixed paraffin embedded
sections [22]. Briefly, we performed microwave antigen retrieval
with sodium citrate buffer pH 6.0 (Zymed Laboratory Inc).
Sections were incubated overnight at 4uC with either mouse
anti-human 4H84 HLA-G antibody (kindly provided by Dr. Mike
McMaster [23] or with a non-immune control serum. Detection
was with anti-mouse Envision plus HRP (DakoCytomation) and
AEC single solution (Zymed Laboratory Inc.). Sections were
lightly stained with hematoxylin (BioGenex).
Luciferase assay
For the firefly luciferase vector we used the pGL3 control vector
(Promega). The 39UTR of HLA-G (containing guanine or cytosine
at position +3142) was amplified by PCR from the pcDNA3
plasmid expressing the HLA-G protein with its 39UTR (described
above) and inserted into XbaI site immediately downstream from
the stop codon. The primers used for this amplification were:
Fw 39UTR XbaI: 59gctctagaattgaaaaggagggagctact 39 and Rv
39UTR XbaI: 59gctctagaaagttctcatgtcttccattt 39. For the genera-
tion of the mutated 39UTR of HLA-G the seed binding region in
the 39UTR was mutated by PCR. First, the upstream fragment
was amplified using the 59 edge primer, used to amplify the
39UTR and an internal 39 primer bearing the mutation (mut
middle: 59agttatagcagtcgtgaccacaaa 39). The downstream frag-
ment was amplified using an internal 59 primer bearing the
mutation (mut middle 59tttgtggtcacgactgctataact 39) and the 39
edge primer used to amplify the 39UTR.
RKO cells were transduced with the lentiviral vectors for miR-
148a, miR-152 and the control miRNA. Cells in 24-well plates
were transfected with LT1 transfection reagent (MiRus) with
200 ng firefly luciferase reporter vector and 50 ng renilla luciferase
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and renilla luciferase activities were measured consecutively with
the Dual-Luciferase Assay system (Promega) 48 h after transfec-
tion. This system allows us to estimate the down-regulation of the
39UTR of HLA-G (which is cloned downstream to the firefly
luciferase gene) by the miRNAs present in the transduced RKO
cells. As an internal control, the firefly luciferase activity is
normalized to renilla luciferase activity (both constructs are co-
transfected to the cells and their activity is measured from a single
sample). To finally determine the effect of the miRNAs on the
39UTR of HLA-G, the normalized firefly luciferase activity, which
was measured in the transduced cells expressing either miR-148a
or miR-152, is further normalized to the firefly luciferase activity
which was measured in the transduced cells expressing the control
miRNA.
FACS staining, antibodies and fusion proteins
The following antibodies were used: DyLight 649-conjugated
goat anti-mouse (Jackson ImmunoResearch), mouse anti human
HLA-G (clone MEM-G9, AbD Serotec), DyLight 649-conjugated
goat anti-human IgG was used as a secondary Ab for the staining
with the fusion protein. For staining of the NK clones, the mAb
anti hILT2 (R&D systems) was used. The fusion protein used in
the present study was LILRB1-Ig (CCM5-N-Ig, containing only
the N-domain of CCM5, was used as a negative control [24]). The
production and the purification of all fusion proteins were
performed as previously described [25]. For FACS staining, the
antibodies were used at concentrations recommended by the
manufacturer. For staining with the fusion proteins, a concentra-
tion of 5 mg/well was used.
Cytotoxicity assay
The cytotoxic activity of LILRB1-positive NK clones against
target cells was assessed in 5-hour 35S-release assays, as described
[25]. E:T ratio was 1:1.
RNA and real-time quantitative PCR
For quantitative RT-PCR analysis of mRNA, cDNA was
produced from a human total RNA survey panel from Ambion
(AM6000). All specimens were polyadenylated with poly(A)
polymerase (Ambion). RNA was reverse-transcribed with Moloney
murine leukemia virus reverse transcriptase (Invitrogen) and 0.5 g
Figure 1. MiR-148a and miR-152 potentially target the 39UTR of HLA-G. (A) Immunohistochemisty performed on first trimester placental
tissue sections. Right panel: negative control. Left panel: HLA-G expression is detected in the trophoblast cell columns and extravillous trophoblasts.
(B) Alignment of the 39UTR of HLA-G (G variant) with the predicted miRNAs: miR-152 left panel, miR-148a right panel. (C) Alignment of the 39UTR of
HLA-G (C variant) with the predicted miRNAs: miR-152 left panel, miR-148a right panel.
doi:10.1371/journal.pone.0033395.g001
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Platinum SYBR Green qPCR SuperMix-UDG with ROX
(Invitrogen). Reaction primers were a 39 adaptor primer and
primers based on the microRNA sequences. The following primers
were used in quantitative real-time PCR analysis of mRNA levels:
Fw HLA-G: 59 tgctgagatggaagcagtcttc 39 Rv HLA-G: 59
actacagctgcaaggacaacca 39 FwUBC: 59cagccgtatatcttcccagact39
RvUBC: 59ctcagagggatgccagtaatcta 39 The following primers
were used to quantify mature miRNA levels by quantitative
realtime-PCR: miR-152: 59 tcagtgcatgacagaacttgg 39 miR-148a:
59 tcagtgcactacagaactttgt 39 miR-16: 59 tagcagcacgtaaatattggcg 39
hU6: 59 atgacacgcaaattcgtgaag 39.
Results
MiR-148a and miR-152 can potentially target the 39UTR
of HLA-G
Recently, several studies suggested that HLA-G expression is
regulated by the cellular miRNAs miR-148a, miR-148b and
miR-152 which have predicted binding sites in its 39UTR
[15,19]. In addition, it was proposed that a C/G polymorphism
at position +3142 affects the expression of HLA-G, such that the
presence of a guanine nucleotide at this position was claimed to
favor binding by these miRNAs [13,15]. Because none of these
studies examined the functional consequences of the down-
regulation of HLA-G by the suggested miRNAs and since they
did not examine whether the polymorphism at position +3142
indeed affects the miR-mediated regulation of HLA-G expres-
sion, we decided to investigate this. We have also studied the
function of the HLA-G targeting miRNAs with regard to the
interaction of HLA-G with NK cells, since under normal
conditions the expression of HLA-G is restricted mainly to the
EVT cells (figure 1A), where it plays an important role in immune
cell modulation [26,27].
To verify that a binding site for miR-148a, miR-148b and miR-
152 exists in the 39UTR of HLA-G we used the RNAhybrid
algorithm [28]. Since the seed region of miR-148b is identical to
that of miR-148a, we reasoned that the activity of these two
miRNAs would probably be similar and we continued our
predictions and later on the experimental analysis only with
miR-148a.
On the basis of the calculation of minimum free energy (mfe) it
can be indeed predicted that both miR-148a and miR-152 can
potentially target the 39UTR of HLA-G (figure 1B). The analysis
further showed that as predicted, the binding of these miRNAs to
the 39UTR is less stable when cytosine is present at position
+3142, because the seed region comprises only six base pair
match, unusually starting from the first nucleotide (figure 1C).
Figure 2. MiR-148a and miR-152 specifically target the 39UTR of HLA-G. (A) Luciferase activity in RKO cells transduced with control miRNA
(black columns), miR-148a (white columns) or miR-152 (grey columns). Results are presented relative to control reporter activity. G/C variant, reporter
containing the WT sequence of the 39UTR of HLA-G, which contains guanine or cytosine at position +3142, as indicated in the figure. Mut, reporter
mutated at the seed sequence of HLA-G 39UTR. Values are mean 6 s.d. of triplicate samples. * P,0.05 (two-tailed Student’s t-test). One out of three
representative experiments is shown. (B) FACS histogram showing GFP levels (indicative for miRNA expression) of the miRNA-infected 721.221 cells.
(C–D) Quantitative real-time PCR analysis of miR-148a (C) or miR-152 (D) in 721.221/HLA-G cells expressing the G variant transduced with the relevant
miRNA or a control miRNA, as indicated in the figure. Results presented relative to U6. One out of three representative experiments is shown.
doi:10.1371/journal.pone.0033395.g002
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To demonstrate that miR-148a and miR-152 directly bind the
39UTR of HLA-G, we performed a dual luciferase reporter assay.
For this, we generated three firefly luciferase constructs: one
contained the 39 UTR of HLA-G with a guanine at position +3142
(G variant), one contained the 39 UTR of HLA-G with a cytosine
at position +3142 (C variant) and another in which the 39UTR of
HLA-G was mutated at the ‘seed sequence’ of the predicted miR-
148a and miR-152 binding sites (the mutation included both
binding sites). We transiently transfected these constructs into the
RKO human colon cancer cells that had been transduced with
miR-148a, miR-152 or a control miRNA. As can be seen in
figure 2A, the luciferase activity was significantly repressed in cells
expressing miR-148a or miR-152, irrespectively of whether G or
C was present at the 39UTR of HLA-G. The mutation at the seed
sequence of the predicted site completely abolished the repression
mediated by each miRNAs (figure 2A). These results indicate that
the predicted binding sites were indeed targeted by both miR-148a
and miR-152 and that the G/C polymorphism has no influence
on miRNA-mediated targeting, despite the unusual seed match
(figure 1C).
MiR-148a and miR-152 down-regulate HLA-G expression
To demonstrate that miR-148a and miR-152 can target HLA-
G we generated transfectants of 721.221 cells that express HLA-G
with its 39UTR (G or C variant, the expression of HLA-G on these
transfectants is shown in the figures below). In addition, we cloned
miR-148a, miR-152 and a control miRNA into lentiviral vectors
that also contain a green fluorescent protein (GFP) cassette, which
allowed us to monitor transduction efficiency. These constructs
were then transduced into the 721.221/HLA-G transfectants. The
lentiviral transduction was extremely efficient (figure 2B). We
confirmed the expression of miR-148a and miR-152 in the
transduced cells by quantitative real-time PCR (figure 2C and D).
Although the analysis shows a much higher expression of miR-152
compared to mir-148a in the transduced cells, the base lines for
each miRNA are not comparable, since different primer sets
(having probably different binding efficiency) are used for the
detection of each of the miRNA. Similar results were obtained
with transfectants of the G and the C HLA-G variants (data not
shown).
We next used our 721.221/HLA-G transfectants expressing
HLA-G with or without its 39 UTR and examined the expression
levels of HLA-G in the presence or in the absence of miR-148a
Figure 3. MiR-148a and miR-152 down-regulate HLA-G expression and reduce LILRB1 binding. 721.221/HLA-G (G variant, A, or C variant,
B) were transduced with the control miRNA, miR-148a or miR-152. The various cells were then stained with anti HLA-G mAb and analyzed by FACS.
One out of three representative experiments is shown. (C) FACS histograms re HLA-G staining of 721.221/HLA-G cells not expressing the 39UTR of
HLA-G. One out of three representative experiments is shown. (D–E) LILRB1-Ig staining of 721.221/HLA-G (G variant, D, or C variant, E) and of 21.221/
HLA-G cells not expressing the 39UTR of HLA-G (F) transduced with control miRNA, with miR-148a or with miR-152. Black histogram: cells transduced
with a control miRNA. Dark grey histogram: cells transduced with miR-148a. Light grey histogram: cells transduced with miR-152. One out of three
representative experiments is shown. (G) Quantitative real-time PCR analysis of HLA-G mRNA levels in 721.221/HLA-G cells (G variant), presented
relative to hUBC. One out of three representative experiments is shown.
doi:10.1371/journal.pone.0033395.g003
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presence of both miRNAs, HLA-G expression (G and C variants)
was down-regulated, compared to the control miRNA. Impor-
tantly, in the absence of the 39UTR of HLA-G, no miRNA-
mediated down-regulation of HLA-G expression was observed
(figure 3C). Thus, both miR-148 and miR-152 directly target the
39 UTR of HLA-G and such targeting lead to HLA-G down-
regulation.
HLA-G is mainly recognized by the inhibitory receptor LILRB1
[6,7] and although LILRB1 can bind also other MHC-I
molecules, its affinity towards HLA-G is the highest [12,29].
Therefore, to test whether the down-regulation of HLA-G by
miR-148a and miR-152 would also lead to decreased binding of
LILRB1 to the transduced cells, we performed FACS staining with
LILRB1-Ig fusion protein (produced as described in [25]). As can
be seen in figure 3D and E, in the presence of miR-148a or miR-
152 the binding of LILRB1-Ig to 721.221/HLA-G cells,
expressing the G variant, (figure 3D) or the C variant (figure 3E)
was indeed decreased. In the absence of the 39UTR of HLA-G the
binding of LILRB1-Ig to the transduced cells was not changed
(figure 3F).
We also transduced JEG-3 cells, which endogenously expresses
HLA-G, with miR-148a and with miR-152 and, as expected,
observed down-regulation of HLA-G (data not shown). However,
we chose not to continue our experiments with this cell line, since
it is not killed by NK cells as it does not express most of the killer
ligands for the NK killer receptors [30].
To reveal the mechanism of the miRNA-mediated repression,
we performed quantitative real-time PCR analysis of the 721.221/
HLA-G cells transduced with either miR-148a, miR-152 or a
control miRNA to evaluate the abundance of the HLA-G
transcript. We observed that in the presence of both miR-148a
and miR-152, the mRNA levels of HLA-G were substentially
decreased (figure 3G). This suggests that the miRNAs’ mode of
action was mRNA degradation and not translational repression.
The same results were obtained for both the G and the C variants
(data not shown).
Functional implications
The interaction between LILRB1 and HLA-G leads to
inhibition of NK cell-mediated cytotoxicity [12]. Therefore, to
test whether the miRNA-mediated down-regulation of HLA-G
expression would affect NK cell cytotoxicity, we isolated LILRB1-
expressing NK clones and tested their activity in cytotoxicity assays
directed against the various 721.221/HLA-G transduced cells. As
can be seen in figure 4, the parental class I MHC negative 721.221
cells [20] were killed by the NK clones. In the presence of a
control miRNA in the 721.221/HLA-G cells, HLA-G was not
down-regulated (figure 3) and indeed a significant inhibition of NK
cytotoxicity could be seen. Importantly, in the presence of miR-
148a or miR-152, when HLA-G was down-regulated (figure 3),
the HLA-G inhibition was significantly abolished, irrespectively of
whether the transfected cells expressed the C (figure 4A) or the G
(figure 4B) variant. Thus, the miR-148a and 152 targeting of
HLA-G resulted in reduced HLA-G expression, reduced LILRB1-
Ig binding and consequently, reduced HLA-G-mediated inhibition
of NK killing.
Expression of miR-148a, miR-152 and HLA-G in the placenta
EVT cells in the placenta express high levels of HLA-G ([4] and
figure 1A). Our final aim was to test whether the expression of the
HLA-G targeting miRNAs and the HLA-G mRNA would be
different among various tissues and cell lines. For that purpose, we
initially determined whether the HLA-G targeting miRNAs are
expressed in three choriocarcinoma cell lines; JEG-3 (HLA-G
positive), BEWO and JAR (HLA-G negative, data not shown) and
observed that the expression of miR-148a and miR-152 were
higher in the BEWO cell line, compared with the JAR and JEG-3
Figure 4. The miRNA-mediate reduction of HLA-G expression
enhances NK cell cytotoxicity. (A–B) 721.221 and 721.221/HLA-G
cells, expressing either the G variant (A) or the C variant (B), transduced
with control miRNA, miR-148a or miR-152, were used as target cells in
killing assays against NK clones expressing LILRB1. The effector: target
(E:T) ratio was 1:1. Values are mean 6 s.d. for triplicate samples.
* P,0.02 (two-tailed Student’s t-test). One out of three representative
experiments is shown.
doi:10.1371/journal.pone.0033395.g004
Figure 5. Expression of miR-148a, miR-152 and HLA-G mRNA in
choriocarcinoma cell lines. (A) Quantitative real-time PCR analysis
for miR-148a (black columns) and miR-152 (white columns) in BEWO,
JAR and JEG-3 cell lines, presented relative to U6. (B) Quantitative real-
time PCR analysis of HLA-G mRNA in BEWO, JAR and JEG-3 cell lines,
presented relative to hUBC. One out of three representative exper-
iments is shown.
doi:10.1371/journal.pone.0033395.g005
MiRNA-Mediated Control of HLA-G
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however, the mRNA of HLA-G could hardly be detected
(figure 5B). In contrast, in the HLA-G-expressing JEG-3 cells
HLA-G mRNA was present (figure 5B). Thus, we concluded that
HLA-G is expressed in JEG-3 cells and not in BEWO and JAR
cells not because of the miRNA activity but rather because the
later two cell lines express little or no HLA-G mRNA.
We next evaluated the expression of the HLA-G mRNA and
miRNAs in various human tissues by using quantitative real-time
PCR. Because the mRNA levels are probably different among
various tissues, an internal normalizer control must be used. For
that purpose mir-16 was used as a reference miRNA, since the
expression of this miRNA is quite ubiquitous in almost all somatic
tissues. As can be seen in figure 6A and B, miR-148a and miR-152
were expressed at relatively low levels in the placenta, compared to
other healthy tissues and as expected, the mRNA levels of HLA-G
were particularly high in the placenta (figure 6C). Because efficient
targeting of a particular gene by miRNAs would happen if the
relevant miRNA is found in sufficient access, we calculated the
expression ratios of HLA-G mRNA and its targeting miRNAs. As
can be seen in figure 6D and E (for miR-148a and miR-152,
respectively), the ratio of the expression of HLA-G mRNA relative
to its targeting miRNAs was the highest in the placenta. This can
be one of the reasons explaining why HLA-G expression is
detected under normal conditions almost exclusively in the
placenta.
Discussion
HLA-G is a non-classical MHC-Ib molecule with a restricted
distribution that is almost completely confined to the EVT cells of
the fetus [4]. As an immunomodulatory molecule [12,29], HLA-G
possesses several unique features, one of which is the inhibition of
decidual NK cell cytotoxicity against the fetal cells [4]. These
decidual NK cells are the dominant lymphocyte population at the
fetal-maternal interface during the first trimester [10,31,32].
It has been suggested that the expression of HLA-G is controlled
by miRNAs, which target the 39UTR of HLA-G mRNA, thereby
down-regulating its expression [15]. Three miRNAs were
suggested to be involved in the HLA-G targeting: miR-148a,
miR-148b and miR-152 [15,19]. In addition, it was proposed that
a C/G polymorphism at position +3142 in the 39 UTR of HLA-G
might affect the efficiency of the miRNA targeting of HLA-G
[13,15]. However, the study by Tan and colleagues [15] focused
on soluble HLA-G and not membrane bound- HLA-G and the
recent study by Zhu XM and colleagues [19] investigated the
function of miR-152 only. Thus, many questions still remain
unanswered. First, there is no information regarding miR-148.
Figure 6. Expression of miR-148a, miR-152 and HLA-G mRNA in various human tissues. (A–C) Quantitative real-time PCR analysis of miR-
148a (A), miR-152 (B) and the mRNA of HLA-G (C) in different healthy tissues, presented relative to miR-16 (A and B) or hUBC (C). (D–E) Ratio of HLA-G
mRNA levels divided by the miR-148a levels (D) or by miR-152 levels (E). One out of three representative experiments is shown.
doi:10.1371/journal.pone.0033395.g006
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determined. Third, proper functional cytotoxicity assays involving
primary human NK cells were not performed [6,7]. In addition,
these studies did not test whether the HLA-G targeting miRNAs
are expressed in the placenta and whether the 39 UTR
polymorphism is really important for the miRNA regulation. In
this manuscript we provide answers to these questions.
We show here that both miR-148a and miR-152 target HLA-G
at its 39UTR and hence down-regulate HLA-G expression. This
down-regulation of HLA-G expression has functional consequenc-
es, as it diminished the binding of the inhibitory receptor LILRB1
to the transduced cells and consequently abolished the HLA-G
mediated inhibition of NK cytotoxicity. Furthermore, we have
found that the C/G polymorphism has no influence on HLA-G
expression. Interestingly, while we show that the +3142 C/G
polymorphism makes no difference to the miR inhibition of HLA-
G, a different polymorphism at the 39UTR of HLA-C did show an
effect on miR-148a inhibition of HLA-C [33].
We further show the physiological implications of the miR-148a
and miR-152 mediated down-regulation of HLA-G expression. As
mentioned above, HLA-G expression is almost completely
restricted to the EVT cells [4]. Therefore, we determined the
miRNA levels and the mRNA levels of HLA-G in three
choriocarcinoma cell lines: JEG-3 (expressing HLA-G), JAR and
BEWO (lacking HLA-G expression) and observed that the
expression of HLA-G in these cell lines is probably dependent
on its mRNA levels. Analysis of the miRNA levels in the placenta
showed very low levels of both miR-148a and miR-152, compared
with other healthy tissues. Moreover, the ratio of HLA-G mRNA
expression relative to its targeting miRNAs is the highest in the
placenta and this might explain the almost exclusive expression of
HLA-G in the placenta.
Several findings suggest that the regulation of HLA-G by miR-
148a and miR-152 extends beyond normal physiological condi-
tions. It has been suggested that HLA-G is important for a
successful pregnancy not only due to its protective effect on the
fetal cells (by inhibiting immune cell function) but also due to its
effect on cytokine and angiogenic factor secretion by NK cells
[9,10]. Low HLA-G expression levels at the fetal-maternal
interface were associated with pregnancy complications, such as
preeclampsia [11] and interestingly, higher levels of miR-152 were
detected in preeclamptic placentas and high levels of miR-148a
were detected in preterm labor placenta [16,34]. In addition,
HLA-G expression is up-regulated in tumors [13] and low levels of
miR-152 and miR-148a were found in tumors, such as breast
cancer and gastrointestinal cancers [13,35]. Nevertheless, although
miR-148a and mi-152 are clearly important in regulating HLA-G
expression in normal tissue and although studies suggested strong
association of both miRNAs and HLA-G with the mentioned
pathologies, further studies are needed to determine the actual
involvement of these miRNAs in pathological conditions.
In summary, our study shows that both miR-148a and miR-152
specifically regulate HLA-G expression by targeting its 39UTR
and that this regulation may control NK-mediated killing, through
the down-regulation of HLA-G.
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